Finanzen von BioHarvest Sciences Inc (BHST)BHSTBioHarvest Sciences Inc

BioHarvest Sciences Inc (BHST) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Products, accounting for 95.2% of total sales, equivalent to $8.10M. Other significant revenue streams include CDMO Services and Elimination of inter-segment transactions. Understanding this composition is critical for investors evaluating how BHST navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, BioHarvest Sciences Inc maintains a gross margin of 57.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -28.37%, while the net margin is -42.04%. These profitability ratios, combined with a Return on Equity (ROE) of -142.50%, provide a clear picture of how effectively BHST converts its operational activities into shareholder value.

In the context of the broader market, BHST competes directly with industry leaders such as OPTH and OMEX. With a market capitalization of $43.30M, it holds a significant position in the sector. When comparing efficiency, BHST's gross margin of 57.51% stands against OPTH's -138.01% and OMEX's N/A. Such benchmarking helps identify whether BioHarvest Sciences Inc is trading at a premium or discount relative to its financial performance.

The company has shown revenue growth, with Q1 2026 revenue at $8.5 million, an 8% year-over-year increase. However, it continues to report net losses, with a Q1 2026 net loss of $2.6 million and a gross margin of 57.51%.